ALG11-CDG
A-L-G-eleven C-D-G
Also known as: Congenital Disorder of Glycosylation Type Ip, CDG-Ip
At a Glance
What is ALG11-CDG?
ALG11-CDG is a rare genetic disorder that affects multiple body systems, primarily due to defects in glycosylation, a process crucial for protein function. It is caused by mutations in the ALG11 gene, which plays a role in the synthesis of glycoproteins. The condition often presents in infancy with symptoms like developmental delay, hypotonia, and failure to thrive. As the disease progresses, individuals may experience seizures, liver dysfunction, and coagulation abnormalities. Early symptoms can be subtle, making early diagnosis challenging but crucial for management and intervention. Late-stage symptoms may include progressive neurological decline and loss of motor skills. The disorder significantly impacts family life, requiring ongoing medical care and support. Prognosis varies, but many affected individuals face severe health challenges and reduced life expectancy. Daily life for those with ALG11-CDG often involves managing complex medical needs and developmental therapies. Early diagnosis and intervention can improve quality of life and help manage symptoms. Families are encouraged to seek genetic counseling to understand the inheritance pattern and implications for future pregnancies.
Medical Definition
ALG11-CDG is a congenital disorder of glycosylation caused by mutations in the ALG11 gene, leading to defective glycoprotein synthesis. Pathologically, it involves impaired N-linked glycosylation, affecting multiple organ systems. Histological findings may include abnormal liver function and neurological anomalies. It is classified under CDG type I disorders, specifically type Ip. Epidemiologically, it is a rare disorder with few reported cases worldwide. The disease course is progressive, with early intervention critical for managing symptoms and improving outcomes.
ALG11-CDG Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Developmental delay manifests as a significant lag in achieving milestones such as walking and talking. This is caused by impaired glycosylation affecting neuronal development and function. Over time, the delay may become more pronounced, impacting learning and social skills. Daily life is affected as patients require ongoing support and therapies to enhance development.
Hypotonia presents as reduced muscle tone, leading to difficulties with posture and movement. The underlying mechanism involves defective glycosylation affecting muscle and nerve function. As the condition progresses, hypotonia can lead to joint instability and delayed motor skills. Patients often need physical therapy to improve muscle strength and coordination.
Seizures in ALG11-CDG can vary in type and frequency, often starting in infancy. They result from abnormal electrical activity in the brain due to disrupted glycosylation pathways. Seizures may become more frequent or severe over time, impacting cognitive development. Antiepileptic medications and regular monitoring are essential to manage this symptom.
Common
Microcephaly is characterized by a smaller head size compared to peers, often noticeable at birth or in early infancy. It occurs due to impaired brain growth linked to glycosylation defects. The condition can lead to intellectual disabilities and developmental challenges as the child grows. Regular monitoring and supportive therapies are important for managing developmental outcomes.
Feeding difficulties may include poor sucking, swallowing issues, and gastroesophageal reflux. These arise from hypotonia and neurological impairments affecting the muscles involved in feeding. Over time, these difficulties can lead to poor weight gain and nutritional deficiencies. Nutritional support and feeding therapies are crucial to ensure adequate growth and development.
Liver dysfunction can manifest as elevated liver enzymes and hepatomegaly. This is due to the accumulation of improperly glycosylated proteins affecting liver function. Over time, liver dysfunction can lead to more severe complications such as fibrosis. Regular liver function tests and supportive care are necessary to manage this symptom.
Less Common
Coagulopathy presents as a tendency to bruise easily or prolonged bleeding from minor injuries. It is caused by defective glycosylation affecting clotting factors. Over time, this can lead to increased risk of bleeding complications. Management includes regular monitoring and, if necessary, clotting factor replacement therapy.
Skeletal abnormalities may include joint contractures and scoliosis. These result from impaired connective tissue development due to glycosylation defects. As the child grows, these abnormalities can affect mobility and posture. Orthopedic interventions and physical therapy are often required to manage these issues.
What Causes ALG11-CDG?
ALG11-CDG is caused by mutations in the ALG11 gene, located on chromosome 13q14.3. The ALG11 gene encodes an enzyme involved in the early steps of N-linked glycosylation, specifically the addition of mannose residues to the growing glycan chain. Mutations in ALG11 can lead to misfolding or instability of the enzyme, impairing its ability to catalyze the transfer of mannose. This disruption in glycosylation affects the proper folding and function of glycoproteins, leading to endoplasmic reticulum stress and impaired cellular trafficking. The accumulation of misfolded proteins can cause dysfunction in the Golgi apparatus and other organelles involved in protein processing. This cellular dysfunction can lead to widespread effects on tissues, particularly those with high glycoprotein turnover like the liver and brain. Neuroinflammation may be triggered as the immune system responds to cellular stress and damage. In the brain, the progressive loss of glycoprotein function can lead to degeneration of white matter and other cerebral structures. Symptoms appear in a pattern reflecting the most affected systems, such as developmental delay, hypotonia, and seizures. Variability in disease severity among patients may be due to differences in the specific mutations, residual enzyme activity, and other genetic or environmental factors. The presence of multiple organ system involvement reflects the ubiquitous role of glycoproteins in cellular function. The immune response may exacerbate tissue damage, contributing to the progression of neurological symptoms. The severity of neurological impairment often correlates with the extent of white matter degeneration. Variability in glycosylation defects can also lead to differences in the onset and progression of symptoms. Understanding the specific molecular and cellular disruptions in ALG11-CDG is crucial for developing targeted therapies.
How is ALG11-CDG Diagnosed?
Typical age of diagnosis: Diagnosis of ALG11-CDG typically occurs in infancy or early childhood, often prompted by developmental delays and multisystemic involvement. Early recognition is crucial due to the progressive nature of the disorder.
Clinicians look for developmental delays, hypotonia, and failure to thrive. A detailed family history is important to identify any hereditary patterns. Physical examination may reveal dysmorphic features and organomegaly. This step helps to focus on congenital disorders of glycosylation as a potential diagnosis.
MRI is the imaging modality of choice, revealing cerebral atrophy and other structural brain abnormalities. These findings support the diagnosis by correlating clinical symptoms with visible brain changes. Imaging helps confirm the diagnosis by excluding other causes of neurodevelopmental delay. Differential diagnoses such as metabolic or other genetic disorders are considered based on imaging results.
Serum transferrin isoelectric focusing is ordered to detect abnormal glycosylation patterns. Abnormal results show a type I pattern, indicating a defect in N-glycan assembly. Elevated liver enzymes and coagulation abnormalities may also be present. These results guide further genetic testing to confirm the specific subtype of CDG.
The ALG11 gene is sequenced to identify pathogenic variants. Mutations such as missense, nonsense, or frameshift are typically found. Identification of biallelic mutations in ALG11 confirms the diagnosis of ALG11-CDG. Results inform family counseling regarding recurrence risks and potential prenatal testing.
ALG11-CDG Treatment Options
Mannose supplementation is a potential treatment approach for some CDG types. It aims to bypass the defective glycosylation pathway. Specific drugs used include oral mannose, which has shown variable efficacy in clinical studies. Evidence for efficacy is limited, with some patients experiencing improvement in liver function and coagulation. Side effects may include gastrointestinal discomfort and the need for frequent dosing.
Techniques include motor skills training and sensory integration therapy. The goal is to improve motor function and enhance developmental milestones. Sessions are typically conducted several times a week, lasting 30-60 minutes. Measurable outcomes include improved muscle tone and coordination. Long-term benefits may include enhanced quality of life and increased independence.
Indicated for patients with severe feeding difficulties and failure to thrive. The procedure involves placing a tube directly into the stomach for nutritional support. Expected benefits include improved nutritional status and growth. Surgical risks include infection and tube dislodgement. Post-operative care involves regular monitoring and tube maintenance.
The care team includes neurologists, geneticists, dietitians, and physical therapists. Interventions focus on symptom management, nutritional support, and developmental therapies. Psychosocial support strategies involve counseling and support groups for families. Family education is provided on disease management and prognosis. Long-term monitoring includes regular follow-up visits and adjustment of care plans as needed.
When to See a Doctor for ALG11-CDG
- Severe seizures — this is an emergency because it can lead to brain damage or be life-threatening if not treated immediately.
- Respiratory distress — immediate medical attention is necessary as it can indicate a life-threatening complication.
- Sudden loss of consciousness — this requires urgent evaluation to rule out serious underlying conditions.
- Frequent vomiting — this is concerning as it may lead to dehydration and requires medical evaluation.
- Developmental delay — significant delays in milestones should be assessed by a specialist to determine the need for interventions.
- Unexplained weight loss — this could indicate malnutrition or other underlying issues and should be investigated by a healthcare provider.
- Mild fatigue — monitor energy levels and ensure adequate rest and nutrition.
- Occasional headaches — keep a diary of frequency and triggers to discuss with a doctor if they persist.
ALG11-CDG — Frequently Asked Questions
Is this condition hereditary?
ALG11-CDG is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Parents of an individual with this condition are carriers, typically without symptoms. There is a 25% chance with each pregnancy for carrier parents to have an affected child. De novo mutations are rare but can occur. Genetic counseling is recommended for families to understand risks and carrier testing options.
What is the life expectancy for someone with this condition?
Life expectancy varies significantly depending on the severity and age of onset. Early onset is associated with a poorer prognosis due to severe complications. Respiratory issues and infections are common causes of mortality. Early intervention and supportive treatments can improve quality of life and survival. Families should have realistic expectations and plan for long-term care needs.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, biochemical tests, and genetic testing. The time from first symptoms to diagnosis can vary, often taking months to years due to the rarity of the condition. Specialists such as geneticists and neurologists are typically involved in the diagnostic process. Delays often occur due to the nonspecific nature of early symptoms. Confirmation is achieved through genetic testing identifying mutations in the ALG11 gene.
Are there any new treatments or clinical trials available?
Research is ongoing, with some promising approaches focusing on gene therapy and enzyme replacement. Novel therapies aim to address the underlying genetic defect, though they are still in experimental stages. Clinical trials can be found on ClinicalTrials.gov by searching for 'ALG11-CDG'. Patients should discuss potential participation in trials with their healthcare provider. New treatments may take several years to become widely available.
How does this condition affect daily life and activities?
ALG11-CDG can significantly impact mobility and self-care, often requiring assistive devices. Educational challenges are common, necessitating individualized learning plans. Social and emotional difficulties may arise due to physical limitations and developmental delays. The condition places a considerable burden on families, who may need additional support. Access to therapies and community resources can greatly enhance quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.ALG11-CDG: novel variant and review of the literature.
Erdal AE, Ceylan AC, Gücüyener K et al. · J Pediatr Endocrinol Metab · 2023 · PMID: 36843332
- 2.ALG11-CDG syndrome: Expanding the phenotype.
Haanpää MK, Ng BG, Gallant NM et al. · Am J Med Genet A · 2019 · PMID: 30676690
- 3.ALG11-CDG: Three novel mutations and further characterization of the phenotype.
Regal L, van Hasselt PM, Foulquier F et al. · Mol Genet Metab Rep · 2015 · PMID: 28649519
- 4.A case of ALG11-congenital disorders of glycosylation diagnosed by post-mortem whole exome sequencing.
Arai Y, Okanishi T, Kanai S et al. · Brain Dev · 2022 · PMID: 35907674
- 5.Identification of two novel variants in ALG11 causing congenital disorder of glycosylation.
Zhao P, Zhang X, Duan Z et al. · Seizure · 2024 · PMID: 39260222
- 6.Improved diagnostics lead to identification of three new patients with congenital disorder of glycosylation-Ip.
Thiel C, Rind N, Popovici D et al. · Hum Mutat · 2012 · PMID: 22213132
- 7.Progressive loss of cerebral structures in ALG11-related congenital disorder of glycosylation.
Fortin O, Vezina G, Steinhorn DM et al. · Pediatr Neurol · 2025 · PMID: 39809108
- 8.Phenotypic and genotypic spectrum of congenital disorders of glycosylation type I and type II.
Al Teneiji A, Bruun TU, Sidky S et al. · Mol Genet Metab · 2017 · PMID: 28122681
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-02